20 assets in Rheumatoid Arthritis

Therapeutic assets addressing Rheumatoid Arthritis, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Naltrexone Rheumatoid Arthritis	Truway Health, Inc.	P4	BBB (74)
Methotrexate Rheumatoid Arthritis	National Institute of Allergy and Infectious Diseases (NIAID)	P3	BB (66)
Jnj-78436735 Rheumatoid Arthritis	National Institute of Allergy and Infectious Diseases (NIAID)	P2	CCC (53)
Moderna Covid-19 Vaccine Rna Rheumatoid Arthritis	National Institute of Allergy and Infectious Diseases (NIAID)	P2	CCC (53)
Monovalent [B.1.351] Cov2 Pres Dtm-As03 Rheumatoid Arthritis	National Institute of Allergy and Infectious Diseases (NIAID)	P2	CCC (53)
Tofacitinib Rheumatoid Arthritis	National Institute of Respiratory Diseases, Mexico	P2	CCC (53)
Disulfiram Rheumatoid Arthritis	University of Oklahoma	P2	CCC (50)
Tozinameran Rheumatoid Arthritis	National Institute of Allergy and Infectious Diseases (NIAID)	P2	CCC (50)
Lb-P6 Rheumatoid Arthritis	LISCure Biosciences	P1	CC (47)
Lb-P8 Rheumatoid Arthritis	LISCure Biosciences	P1	CC (47)
1-235-TUMOR NECROSIS FACTOR RECEPTOR (HUMAN) FUSION PROTEIN WITH 236-467-IMMUNOGLOBULIN G1 (HUMAN .GAMMA.1-CHAIN FC FRAGMENT), DIMER Rheumatoid Arthritis	Duke University	P1	CC (43)
azd0120 Rheumatoid Arthritis	AstraZeneca	P1	CC (43)
bnt162b2 Rheumatoid Arthritis	National Institute of Allergy and Infectious Diseases (NIAID)	P2	CC (43)
Cabozantinib Rheumatoid Arthritis	National Cancer Institute (NCI)	P1	CC (43)
hbi0101 cart Rheumatoid Arthritis	Polina Stepensky	P1	CC (43)
Ipilimumab Rheumatoid Arthritis	National Cancer Institute (NCI)	P1	CC (43)
Nivolumab Rheumatoid Arthritis	National Cancer Institute (NCI)	P1	CC (43)
her2bbζ/cd19t+ t cells Rheumatoid Arthritis	PersonGen BioTherapeutics (Suzhou) Co., Ltd.	Early P1	C (39)
Mtm-H-001 Rheumatoid Arthritis	Beijing GoBroad Hospital	N/A	D (30)